Novartis/GSK – expensive restructuring?

Apr 22, 2014 : GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs.
61 - 72 LEX (100)